Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors

NCT02298959 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02298959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02298959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 8, 2015
Completion date
January 20, 2027
Enrollment
59 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iv cutaneous melanoma ajcc v8, metastatic colorectal carcinoma, metastatic malignant solid neoplasm, metastatic melanoma, metastatic ovarian carcinoma, metastatic renal cell carcinoma, platinum-resistant ovarian carcinoma, recurrent melanoma, recurrent renal cell carcinoma, refractory melanoma, refractory renal cell carcinoma, sarcoma, stage iv colorectal cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv renal cell cancer ajcc v8